#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepatocellular carcinoma Myelofibrosis Osteochondrodysplasia Prophylaxis against transplant rejection Marginal zone lymphoma refractory Synovitis Neuropathic arthropathy Cardiomyopathy Renal cancer metastatic Familial haemophagocytic lymphohistiocytosis Penile squamous cell carcinoma Plasma cell myeloma refractory Muscular dystrophy Canavan disease Adenocarcinoma pancreas More trials…

    Learn about Rare Diseases

    Richter’s syndrome – Treatment Myxofibrosarcoma – Basic Information Acute respiratory distress syndrome Systemic sclerosis pulmonary – Life with Disease Sarcoidosis – Diagnostics Synovial sarcoma recurrent – Life with Disease Malignant fibrous histiocytoma – Life with Disease Cystic fibrosis – Basic Information Ewing’s sarcoma recurrent Epidermolysis bullosa – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tapderimotide BI 456906 Busulfan Clotrimazole Antipsychotics Tezepelumab Concizumab Lactose Festuca Rubra Pollen Murcidencel USNOFLAST Ofloxacin Gsk4381562A MAGNESIUM ACETATE TETRAHYDRATE Pentixafor Ipilimumab Gskvx000000014593 Teverelix S-241656 GOVORESTAT More therapies…

    Learn about Your Condition

    Pseudoxanthoma elasticum Insulin resistance Breast proliferative changes Alcohol abuse Staphylococcal bacteraemia Merycism Angina pectoris Breast cancer Colorectal adenocarcinoma Hypochromic anaemia Ataxia telangiectasia Anal fistula Sarcoma Vulval cancer recurrent Hereditary optic atrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metastatic malignant melanoma

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Metastatic malignant melanoma
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • RP2
    • RP3
    France Germany Greece Poland Spain

  • Study of TIL therapy combined with peginterferon alfa-2a and nivolumab for patients with metastatic melanoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • TIL CELLS
    • Zirconium (89Zr) Crefmirlimab Berdoxam
    The Netherlands

  • Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Trametinib
    • Dabrafenib Mesylate
    Austria Czechia Denmark France Germany Hungary +2

  • Study on Adding Diclofenac to PD-1 Inhibitor Therapy for Patients with Metastatic Melanoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Pantoprazole
    • Diclofenac Sodium
    • Nivolumab
    Germany

  • Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Diphenhydramine
    • Dexamethasone Phosphate
    • Tebentafusp
    Austria Belgium France Germany Italy Poland +1

  • Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria Belgium Czechia Finland France Germany +5
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!